Skip to main content

Table 1 Demographic details for each cohort

From: ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies

 

Control

PD

DLB

p value

Sex (M:F)

6:6

7:4

7:4

0.68+

Age (years)

77 ± 10 (62–92)

78 ± 6 (71–88)

78 ± 6 (67–88)

0.94

PMD (hours)

21 ± 11 (6–36)

13 ± 7 (3–23)

24.5 ± 12 (4–39)

0.07

Duration (years)

-

19 ± 8 (8–36)

7 ± 4 (1–13)

<0.001

Braak PD stage #

-

9 IV; 2 V/VI

0 IV; 11 V/VI

<0.001+

NIA Regan AD *

0/12

0/11

1/11

0.37+

CDR

0.0 ± 0.1 (0–0.5)

0.1 ± 0.2 (0–0.5)

2.4 ± 0.8 (1–3)#

<0.001+

Aβ42 (μg/ml) ^

13 ±8 (7.4-24.9)

16.5 ± 10 (7.0-31.1)

31.4 ± 11(17.8-42.3) #

0.046

  1. # [1].
  2. * [3] None of the 11 PD cases and only 1 of the 11 DLB cases reached diagnostic criteria for Alzheimer’s disease, with neuritic beta-amyloid plaques and tau-positive neurofibrillary tangles present in this single DLB case. All other DLB cases displayed diffuse beta-amyloid plaques.
  3. ^Data obtained from parahippocampal cortices.
  4. #Different from other groups on posthoc protected t test.
  5. +Chi-square test, Analysis of variance (ANOVA).
  6. Data are presented as mean ± standard deviation (range) for post-mortem delay (PMD), age at death (Age), disease duration (Duration), clinical dementia rating scale (CDR) and β-amyloid 1–42 protein levels (Aβ42).